Foot-and-mouth disease vaccine
Inventors
Dominowski, Paul Joseph • Hardham, John Morgan • Jackson, James Alan • Gay, Cyril Gerard • Rodriguez, Luis Leandro • Krug, Peter William • Rieder, Aida Elizabeth
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.
Core Innovation
Foot and Mouth Disease (FMD) is a highly contagious viral disease affecting cloven-hoofed animals, causing economically devastating outbreaks globally. Current vaccines require production in high-containment facilities due to the need to grow virulent virus in large volumes, which entails significant risk and cost, as well as difficulties in differentiating infected from vaccinated animals (DIVA). The problem is worsened by virus persistence, where vaccinated animals can become carriers, posing infection risks despite showing no symptoms, necessitating slaughter of whole herds during outbreaks.
The invention provides immunogenic compositions comprising an antigen component equivalent to 0.5-20 μg of FMD virus and an adjuvant component comprising an emulsion with an oily phase (at least 50% v/v of the composition), an immunostimulatory oligonucleotide (preferably CpG-containing), and a polycationic polymer (e.g., DEAE dextran). These compositions enable effective protection with a significantly reduced antigen dose and can reduce FMD virus persistence. The antigen may be inactivated or attenuated, including genetically engineered FMD virus strains with deletions and antigenic markers to facilitate DIVA.
The invention also provides methods of preventing FMD by administering such immunogenic compositions to animals such as cattle, sheep, pigs, and goats. Moreover, the compositions and methods reduce viral persistence in ruminants and allow modified herd management practices whereby vaccinated animals, upon suspected exposure, are not slaughtered but may be quarantined or relocated, reducing economic losses and improving disease control.
Claims Coverage
The claims disclose methods of herd management using immunogenic compositions with specific antigen and adjuvant components, comprising several inventive features.
Use of an immunogenic composition with defined antigen dose and adjuvant components for herd management
A method of herd management involving administering to each herd member an immunogenic composition comprising an antigen component of 6-20 μg of FMD virus per dose; an emulsion containing oil; 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; and 75-200 mg of a polycationic carrier per dose, enabling vaccinated animals to not be slaughtered upon suspected FMD infection.
Controlling quarantine duration for vaccinated animals
A method wherein, upon suspected contact with FMD infection, vaccinated animals are quarantined for 0-30 days, using the immunogenic composition defined by the antigen and adjuvant components.
Relocation of vaccinated animals beyond infected premises
A method allowing, upon suspected contact with FMD infection, vaccinated herd members to be moved beyond the infected premises while receiving the defined immunogenic composition.
Specification of antigen dose ranges within herd management methods
Methods where the immunogenic composition comprises antigen doses refined to 6-18 μg, 6-12 μg, or 8-12 μg of FMD virus per dose.
Use of diethylaminoethyl (DEAE) Dextran as the polycationic polymer
The polycationic carrier in the immunogenic composition is specified as DEAE Dextran for improved immune response in herd management.
Inclusion of CpG immunostimulatory oligonucleotide with specific nucleotide sequence
The immunostimulatory oligonucleotide contains CpG motifs, including at least 15 contiguous nucleotides of SEQ ID NO: 8, to enhance immunogenicity.
Use of light mineral oil in the emulsion with defined oily phase volume
The oil in the emulsion is a light mineral oil, with the oily phase constituting between 50.01% and 55% v/v of the immunogenic composition, ensuring effective vaccine delivery and immune stimulation.
The claims encompass methods of herd management using immunogenic compositions with specified ranges of FMD antigen, CpG oligonucleotides, and polycationic carriers in an oil emulsion, facilitating non-lethal management of infected herds via vaccination, quarantine, and movement strategies.
Stated Advantages
Allows effective FMD protection with lower antigen doses, reducing vaccine production costs.
Enables reduction or prevention of FMD viral persistence in vaccinated ruminants.
Supports modified herd management practices, avoiding slaughter of vaccinated animals upon suspected infection.
Facilitates quarantine duration reduction and movement of vaccinated animals, improving outbreak control and economic outcomes.
Documented Applications
Prevention of Foot and Mouth Disease in cloven-hoofed animals including cattle, pigs, sheep, and goats.
Reduction of FMD viral persistence in ruminants through vaccination.
Herd management practices involving vaccination where vaccinated animals are not slaughtered after suspected FMD exposure.
Use in vaccination regimes enabling quarantine durations of 0-30 days for exposed vaccinated animals.
Relocation of vaccinated animals beyond infected zones during outbreak containment.
Interested in licensing this patent?